We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The role of L-methylfolate in depressive disorders [corrected] [published erratum appears in PRIM PSYCHIATRY 2009 Feb;16(2):18].
- Authors
Farah A
- Abstract
Major depressive disorder (MDD) is a debilitating and often recurrent illness. An initial antidepressant trial is effective at achieving remission for ~30% of patients when prescribed as monotherapy, with the majority of patients returning as partial or non-responders. Switching antidepressants or adding augmentation agents are standard therapeutic options used to achieve and maintain remission. Suboptimal serum and red blood cell folate levels have been associated with a poorer response to antidepressant therapy, a greater severity of symptoms, later onset of clinical improvement, and overall treatment resistance. This Expert Review Supplement reviews the evidence for L-methylfolate as an augmentation agent in depression and discusses its clinical use elaborated by three clinical presentations.
- Publication
Primary Psychiatry, 2009, Vol 16, Issue 1, p1
- ISSN
1082-6319
- Publication type
Journal Article